Mergers and acquisitions

Vaccine
#AstraZeneca #Bioconjugates #Immunology / Virology & Vaccines #Mergers and acquisitions

AstraZeneca buys conjugate vaccine developer Omniose

Omniose is to be acquired by AstraZeneca, following a productive three-year exclusive research collaboration between the two companies.  Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit.   The acquisition brings Omniose’s… Read More

#Business & Investment #News

#CDMO #Lonza #Manufacturing #Merck #Mergers and acquisitions

Lonza signs agreement to acquire US CDMO network from Merck

Lonza has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck (Darmstadt, Germany) at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs. The acquisition expands Lonza’s US CDMO manufacturing footprint from four to nine sites and complements its global network… Read More

#News

siRNA
#Merck #Mergers and acquisitions #Silence Therapeutics #siRNA

Merck KGaA buys Silence Therapeutics for $1.3 billion

Merck KGaA is to acquire Silence Therapeutics, a biotechnology company developing precision engineered medicines using siRNA technology.   Merck has agreed to acquire Silence in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion.  “We are pleased… Read More

#Business & Investment #News #Trending News

Deal making
#Mergers and acquisitions #Neurodegenerative disorders #Rare disease #Shionogi

Shionogi expands rare disease portfolio with IntraBio buyout

Shionogi has announced plans to acquire IntraBio, a biopharmaceutical company developing therapies for neurodegenerative diseases, for $2 billion.  The transaction will add Aqneursa (levacetylleucine) and IntraBio’s capabilities in the rare disease area to Shionogi’s growing portfolio.  Aqneursa was approved by the FDA in September 2024… Read More

#Business & Investment #News

#Human cell models #Mergers and acquisitions #Preclinical development #Revvity

Revvity acquires human cell model specialist

Revvity has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specialising in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases.   The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s… Read More

#Business & Investment #News

Glucagon-like peptide 1
#GLP-1 #Menarini #Mergers and acquisitions #Obesity #Weight loss

Gan & Lee and Menarini agree $843m deal for GLP-1 candidate

Gan & Lee Pharmaceuticals and Menarini have announced plans to collaborate on the registration and commercialisation of Gan & Lee’s glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide.  The drug is under development for the treatment of adults with obesity or overweight, administered once every two weeks. … Read More

#Business & Investment #News

handshake
#Autoimmune disease #Eli Lilly #Immunology #Mergers and acquisitions

Merida acquisition strengthens Lilly’s immunology capabilities

Eli Lilly has announced plans to acquire Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases.  Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions.   The… Read More

#Business & Investment #News #Trending News

Bispecific antibodies
#Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Roche

Roche acquires trispecific antibody for $1.5bn

Roche has acquired exclusive global rights to develop, manufacture, and commercialise SIM0660, a trispecific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases.  Under the terms of the agreement, developer Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including… Read More

#Business & Investment #News

#epilepsy #Mergers and acquisitions #Neuroscience

SK Biopharmaceuticals licences epilepsy drug from Biohaven

Biohaven and SK Biopharmaceuticals have agreed a strategic global licensing and collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven’s Kv7 ion channel platform.  The platform is led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase II/III development… Read More

#Business & Investment #News

#Mereo BioPharma #Mergers and acquisitions #Rare disease #Sentynl Therapeutics

Sentynl expands rare disease portfolio with alvelestat purchase

Sentynl Therapeutics and Mereo BioPharma have entered into an option and license agreement for the US commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).   Alvelestat is a neutrophil elastase inhibitor being readied for Phase III and, if approved, would be the… Read More

#Business & Investment #News

#AstronauTx #Mergers and acquisitions #Neurology #Neuroscience

AstronauTx acquires neurological disease programme from Saniona

AstronauTx has secured the exclusive worldwide rights to research, develop, manufacture and commercialise therapeutic candidates arising from its collaboration with biopharma company Saniona.  Saniona and AstronauTx entered into a research collaboration and option agreement in 2023 to discover new treatments for neurological conditions by modulating a novel,… Read More

#Business & Investment #News

Merge road sign
#CNS #Mergers and acquisitions #Supernus Pharmaceuticals

Merger creates CNS biopharma worth $2.2 billion

Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company.  The companies expect the transaction to generate significant value for stockholders of both companies, realising… Read More

#Business & Investment #News

#Mergers and acquisitions #Processa Pharmaceuticals #Vidya Therapeutics

Processa Pharmaceuticals buys Vidya Therapeutics

Processa Pharmaceuticals has acquired Vidya Therapeutics, a clinical-stage biotechnology company developing VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases.  The product is initially focused on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria (CSU) and relapsing multiple sclerosis (RMS).  Concurrent… Read More

#Business & Investment #News

Antibodies
#Autoimmune disease #Kira Pharmaceuticals #Mergers and acquisitions #Mirador Therapeutics

Mirador Therapeutics licenses anti-C5a antibody from Kira Pharmaceuticals

Mirador Therapeutics has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation.   The agreement expands Mirador’s precision immunology portfolio into inflammatory vascular disease. Kira will receive $12 million upon signing.  The… Read More

#Business & Investment #News

Novartis head office
#Biotech #Mergers and acquisitions #Myricx Bio #Novartis

Novartis acquires ADC developer Myricx Bio 

UK biotech Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion.  The companies say the acquisition advances antibody-drug conjugate (ADC) innovation by bringing together the strengths of Novartis in oncology with Myricx Bio’s two lead ADC assets and next-generation first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform, having potential… Read More

#Business & Investment #News